(주)셀레브레인

글로벌 유전자·세포치료제 개발을 선도하는 바이오 혁신기업 

연혁

  • 2023
    12
    Ph.1 IND application for GBM
    9
    Head office relocated
  • 2022
    9
    Relocation of R&D center
    2
    License-in from Ajou University
  • 2021
    12
    Series-A fund raised
    6
    Renewal of the venture company certification (2021.04 ~ 2024.04)
    3
    Initiation of Phase 0 trial for rGBM
    2
    IND approval with Hanmi Pharm. Co., Ltd
  • 2020
    4
    Opening of branch office in Gyeonggi-do
  • 2019
    12
    License-in from Ajou University
    9
    Pre A fund raised
    4
    Certification of a venture company
  • 2018
    6
    Seed investment
    3
    Established as a research institute company of Ajou University